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Franca Benini1*† and Egidio Barbi2†Abstract
Codeine is a mild opioid widely used as an analgesic in various age groups, including various pediatric settings. It is
a prodrug that owes its analgesic effect almost entirely to the principal metabolite: morphine. The genetic
polymorphisms can contribute to making the pharmacokinetics of codeine hard to predict and this it is particularly
important in the pediatric population because infants and children have greater susceptibility to the side-effects of
morphine. In recent years there have been several reports in the literature on the risks relating to the use of codeine.
In August 2012, the American Food and Drugs Administration began to revise its recommendations for the safe use of
codeine and in February 2013, established that codeine should not be used for postoperative pain control in children
undergoing adenoidectomy and/or tonsillectomy and did restrict the use of this drug in the pediatric population. In
June 2013, the European Medicine Agency opted the same decision. In July 2013, the Agenzia Italiana del Farmaco
prohibit the use of medicines containing codeine for patients under 12 years old and recommended a limited
use of the drug, in many other situations. Complying with these recommendations naturally means changing
habits and treatment strategies well established in pediatric practice, but other drugs, tools and techniques
available enable us to continue to assure an adequate pain control in pediatric patients, irrespective of their age
and situation. The article proposes same alternatives of pain control drugs.
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Codeine is a mild opioid widely used as an analgesic in
various age groups, including various pediatric settings.
It is a prodrug that owes its analgesic effect almost en-
tirely to the principal metabolite: morphine. Cytochrome
P450 2D6 (CYP2D6) converts codeine into morphine in
the liver. This process is genetically determined and the
enzyme’s activity varies from one person to another. The
enzyme is more active in some individuals (termed
ultra-rapid metabolizers), converting codeine into mor-
phine more quickly and completely. This also means
that, after they have been administered the right dose of
the drug for their ideal weight and age, these individuals
have higher blood levels of morphine than controls. The
prevalence of this mutation varies among different ethnic
groups, ranging from 5% to 29%. Meanwhile, a variable
proportion of 5-10% of the population has a limited* Correspondence: benini@pediatria.unipd.it
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article, unless otherwise stated.CYP2D6 enzymatic activity (poor metabolizers), in which
case the amount of morphine produced by their metabol-
ism of codeine is very small.
Like the polymorphism of cytochrome 450 isoenzyme
CYP2D6, other genetic polymorphisms can also contrib-
ute to making the pharmacokinetics of codeine hard to
predict (including variations in morphine metabolism,
its passage through the blood–brain barrier, and differ-
ent receptor kinetics). All these genetic variations can
have clinical consequences, and an unfortunate combin-
ation of different polymorphisms can give rise to toxic
levels of morphine - even after an appropriate dose of
codeine has been administered - with a higher risk of
side-effects.
This is particularly important in the pediatric popula-
tion because the fact of being newborn or an infant is asso-
ciated per se with a greater susceptibility to the side-effects
of morphine [1,2].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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In recent years there have been several reports in the lit-
erature on the risks relating to the use of codeine.
In 2007 Madadi [3] reported on the death of a newborn
breastfed by a mother who had been given codeine to con-
trol postpartum pain. An analysis of the mother’s geno-
type revealed that she was an ultra-rapid metabolizer and
the newborn’s blood contained toxic levels of morphine.
Ciszkowski reported in 2009 [4] on a two-year-old
child who died after being sent home on codeine therapy
(at the correct dose) to control postoperative pain after
an adenotonsillectomy. The autopsy showed that the in-
fant had pneumonia and high blood levels of morphine.
Genotyping confirmed that the child was a hyper-
metabolizer. The author made the point that, combined
with the high morphine levels, other factors may have
contributed to the fatal outcome, i.e. pneumonia and
sleep apnea may have exacerbated the infant’s hypox-
emia, consequently altering the mu receptors and in-
creasing their sensitivity to morphine.
Kelly et al. [5] reported on 3 fatal cases of respiratory
depression and 1 of severe respiratory insufficiency oc-
curring between 2009 and 2012 in children between two
and five years old. They were all ultra-rapid metabolizers
who had been given codeine after tonsillectomy and/or
adenoidectomy for obstructive sleep apnea syndrome
[5]. Here again, these patients had several risk factors,
i.e. they were young children, they had obstructive
sleep apnea, they had undergone surgery, and they
were also ultra-rapid CYP2D6 metabolizers.
Niester et al. [6] conducted a literature review on the
cases of respiratory depression due to opioids in a
pediatric setting (0 to 12 years old). Among 24 reports,
they identified 27 cases of severe respiratory depression
induced by opioids, 7 of which were fatal. Eight cases
were due to an overdosage of the drug; for the other 19,
three specific causes were identified: opioid accumula-
tion due to a renal insufficiency that had been over-
looked; patients who were hyper-metabolizers; and codeine
therapy used for patients who had tonsillectomy and/or
adenoidectomy for recurrent obstructive sleep apnea or
tonsillitis (and whose respiratory depression probably coin-
cided with a hypoxia that exacerbated their susceptibility to
a drug-related respiratory depression.
In 2013, Friedrichsdorf [7] described three cases of
children ranging from four to 10 years old dying at
home due to codeine toxicity. All three were overweight
or obese, but the prescribed dose of the drug was appro-
priate for their ideal weight. In this article, obesity and
polypharmacology were mentioned as concomitant causes
of toxicity.
In August 2012, the American Food and Drugs Ad-
ministration (FDA) began to revise its recommendations
for the safe use of codeine. From 1969 to 1 May 2012,there were 13 reported cases of adverse events or death
in patients on codeine therapy (10 deaths and 3 cases of
severe respiratory insufficiency), in patients ranging from
21 months to 9 years of age. Most of these reports con-
cerned children with obstructive apnea who had been
given appropriate doses of the analgesic for postopera-
tive pain control after tonsillectomy and/or adenoidect-
omy (8 cases), or during the course of respiratory
infections (3 cases). Among the 7 cases in which a gen-
etic study on cytochrome P450 2D6 was conducted, an
increased enzyme activity was always documented: 3
were “ultra-rapid metabolizers”, 1 was a “probable ultra-
rapid metabolizer”, and 3 were “extensive metabolizers”.
All these patients had respiratory problems, which were
judged to be factors capable of increasing these young
patients’ susceptibility to the respiratory depressant ef-
fects of toxic levels of morphine [8-10].
Since it is impossible to identify children who are
ultra-rapid metabolizers of codeine in advance, and
given the correlated risks (albeit only in rare reports),
the FDA established that codeine should not be used for
postoperative pain control in children undergoing ade-
noidectomy and/or tonsillectomy. While the FDA did
not restrict the use of codeine for pain control in other
clinical situations, it did reiterate the need to monitor
patients for the drug’s efficacy and side-effects (particu-
larly sleepiness, sedation, breathing rate and characteris-
tics) continuously during the treatment.
In February 2013, the FDA reported on another 3
deaths and 1 case of severe respiratory insufficiency in
young patients treated with codeine. All the children in-
volved were ultra-rapid or extensive metabolizers, they
developed high blood levels of morphine, and they were
given codeine therapy to control postoperative pain after
tonsillectomy and/or adenoidectomy [11]. On this occa-
sion, the FDA confirmed its ban on the use of codeine
in children undergoing surgery for tonsillectomy and/or
adenoidectomy for obstructive apnea. It also stated that,
in the event of drugs containing codeine being used for
other conditions, they should be prescribed at the lowest
effective dose, for the shortest possible period of time,
and only administered as necessary, not according to
any fixed schedule.
In October 2012, the European Medicine Agency (EMA)
also began a review procedure on the risk-benefit profile
of products containing codeine used for pain control in
pediatric patients. At the end of the review process, com-
pleted in mid-2013 (EMA, 28 June 2013), the EMA opted
to prohibit the use of medicines containing codeine for
patients under 12 years old, and extended this ban up to
18 years of age in the case of patients undergoing tonsil-
lectomy and/or adenoidectomy for obstructive sleep
apnea. It also recommended that, when used, these
drugs should be prescribed at the minimum effective
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tinuous monitoring of their efficacy and side-effects [12].
On 29 July 2013, the Agenzia Italiana del Farmaco
(AIFA) prohibited the use of codeine for pain control in
certain categories of patients, i.e. [13]:
 children under 12 years of age,
 children and adolescents (0–18 years old)
undergoing adeno/tonsillectomy for obstructive
sleep apnea syndrome,
 patients known to be hyper-metabolizers, and
 breastfeeding women.
It also recommended that products containing codeine
be avoided for children over 12 with any respiratory
function impairment, and it reiterated the EMA consid-
erations on the dosage and duration of the treatment.
In the light of the above, it is worth adding some com-
ments and conclusions:
 The reported adverse events are very rare and
multifactorial, but catastrophic in their evolution.
 The feasibility of performing diagnostics to predict
which might become critical is very limited and
uncertain.
 Monitoring side-effects may help to contain the
negative evolution of toxicity episodes, but cannot
prevent their onset.
 The literature available on the pharmacokinetics,
pharmacodynamics and toxicity of codeine is dated,
limited, and does not allow for any final conclusions
to be drawn.
 Codeine is scarcely or not at all effective in some
children who carry the cytochrome 450 isoenzyme
CYP2D6 polymorphism.
 Other analgesics are available for use in the pediatric
setting as an alternative to codeine.
Hence the recommendations of the FDA, EMA and
AIFA, and it is important to bear these protective measures
in mind when deciding whether or not to use codeine.
Complying with these recommendations naturally
means changing habits and treatment strategies well
established in pediatric practice, but other drugs, tools
and techniques available enable us to continue to assure
an adequate pain control in pediatric patients, irrespect-
ive of their age and situation.
Recent data have demonstrated that, among the non-
opioids, there are drugs that are very well known, easy
and safe to use but that continue even today to be little
used in children (and often in insufficient doses). This is
the case of paracetamol and ibuprofen, for example,
which are indicated for a great deal of situations requir-
ing mild-to-moderate pain control in pediatric age [14].Among the mild opioids, tramadol is the best alterna-
tive to codeine in the pediatric setting. Tramadol is a
synthetic 4-phenylpiperidine codeine analog. Its anal-
gesic potency is considered to be medium, acting on
both opioid-sensitive and opioid insensitive pain through
multiple mechanisms of action. It is considered a weak
mu-opioid receptor agonist. It inhibits the neuronal re-
uptake of serotonin and norepinephrine. It displaces
serotonin stores within the spinal cord, facilitating the
descending pain inhibitory pathways. It may have select-
ive spinal and local anesthetic effects on peripheral
nerves [15]. The opioid activity of tramadol results from
a low affinity for binding to mu-opioid receptors with no
affinity for delta or kappa opioid receptors. The drug is
bio-activated by CYP2D6 to the opioid receptor agonist
O-desmethyltramadol, which contributes to the anal-
gesic effect because of its 300-fold higher affinity for
binding to mu-opioid receptors [15,16].
The analgesic efficacy and safety of tramadol in chil-
dren have been confirmed by various studies in different
settings, in both inpatients and outpatients, including
cases of adenotonsillectomy in children with obstructive
sleep apnea [15,17-25].
The advantages of tramadol over opioids lie mainly in
the lower incidence of major side effects such as ventila-
tory depression and sedation. An ample, up-to-date litera-
ture search brought to light no reports of any respiratory
depression or sedation in the pediatric age group. On the
other hand, dose-dependent hypercapnia was reported in
one group of neonates, suggesting that tramadol affects
the respiratory center during the neonatal period [26].
To the best of our knowledge, there are only three
case reports in the literature of tramadol at therapeutic
doses inducing respiratory depression in adults: one of
these involved an CYP2D6 ultra-metabolizer patient
with renal impairment; the other two cases are contro-
versial, occurring in patients concomitantly using phen-
tanyl and other anesthetics [27-29].
Nausea-vomiting, pruritus and rash are the most fre-
quently reported side-effects of tramadol, occurring with
a frequency of around 10%, 7% and 4%, respectively [30].
The importance of pharmacogenetics has been highlighted
when it comes to considering the risks of tramadol causing
adverse effects: CYP2D6 gene duplication carriers are at a
statistically significant higher risk of developing adverse
events (mainly vomiting and nausea), without any pharma-
cokinetic differences. The proportion of the population with
this gene duplication is reportedly quite high in southern
Europe and northern Africa (up to 7% in Spain and Turkey,
30% in Ethiopia and Saudi Arabia) [31].
In Italy, tramadol is licensed for use in children over
1 year old.
In conclusion, judging from the literature, tramadol
seems to be safe for use in children, be they inpatients
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codeine-related deaths, however, we should bear in mind
that specific risk factors (adeno-tonsillectomy, sleep
apnea, obesity, renal impairments, the neonatal period)
could have a role in any onset of adverse events in ultra-
metabolizers. The body of evidence currently available is
still too limited to thoroughly ascertain tramadol’s safety
in such cases, however. In children with specific risk fac-
tors, it may therefore be appropriate to limit the use of
tramadol to monitored settings while we wait for more
data to emerge.
In cases of moderate to severe pain, strong opioids (es-
pecially morphine and oxycodone) provide a valid and
appropriate alternative to codeine. Used correctly, these
drugs are effective, manageable and very safe [14].
Conclusion
The limitations imposed on the use of codeine in
pediatric practice should not have the wholly unjustified
effect of triggering or exacerbating concern or fears
about prescribing analgesic drugs in general, and opioids
in particular, for children. They should contribute in-
stead to an increasing our awareness, attention to pa-
tients’ symptoms, and competent, critical analysis of the
many options currently available for pain control.
All newborn, infants and children have a right to pain
control, and the appropriate tools for achieving this aim
are available to all health-care professionals.
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